Pharmaceutical composition for the prevention or treatment of infectious RNA virus infections
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- SHIN POONG PHARMA CO LTD
- Filing Date
- 2021-03-25
- Publication Date
- 2026-07-23
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 0007894319000007 
Figure 0007894319000008 
Figure 0007894319000009
Abstract
Claims
1. A pharmaceutical composition for the prevention or treatment of a respiratory illness caused by coronavirus infection, namely COVID-19, comprising a therapeutically effective amount of pyronaridine or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
2. A pharmaceutical composition for the prevention or treatment of respiratory illness caused by coronavirus infection, namely COVID-19, comprising a therapeutically effective amount of artemisinin or a derivative thereof, together with a pharmaceutically acceptable carrier, A pharmaceutical composition wherein the derivative of artemisinin is selected from the group consisting of dihydroartemisinin, artesunate, artemether, and arteether.
3. A pharmaceutical composition for the prevention or treatment of respiratory illness caused by coronavirus infection, namely COVID-19, comprising a therapeutically effective amount of pyronaridine or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of artemisinin or a derivative thereof, together with a pharmaceutically acceptable carrier, A pharmaceutical composition wherein the derivative of artemisinin is selected from the group consisting of dihydroartemisinin, artesunate, artemether, and arteether.
4. The pharmaceutical composition according to claim 1 or 3, characterized in that the pharmaceutically acceptable salt of pyronarizine is selected from the group consisting of phosphate, sulfate, hydrochloride, acetic acid hydrochloride, methanesulfonate, benzenesulfonate, toluenesulfonate, maleate, and fumarate.
5. The pharmaceutical composition according to claim 4, characterized in that the pharmaceutically acceptable salt of pyronarizine is a phosphate.
6. The pharmaceutical composition according to claim 3, characterized in that the weight ratio of pyronaridine or a pharmaceutically acceptable salt thereof to artemisinin or a derivative thereof is 10:1 to 1:
10.
7. The pharmaceutical composition according to claim 6, characterized in that the weight ratio of pyronaridine or a pharmaceutically acceptable salt thereof to artemisinin or a derivative thereof is 1:1 to 6:
1.
8. The pharmaceutical composition according to claim 7, characterized in that the weight ratio of pyronaridine or a pharmaceutically acceptable salt thereof to artemisinin or a derivative thereof is 3:
1.
9. The pharmaceutical composition according to claim 2 or 3, characterized in that the derivative of artemisinin is artesunate.
10. A pharmaceutical composition according to any one of claims 1 to 3, further comprising at least one other antiviral agent.
11. The pharmaceutical composition according to claim 10, characterized in that the other antiviral agent is selected from the group consisting of a viral replication inhibitor, a helicase inhibitor, a viral protease inhibitor, and a viral cell entry inhibitor.
12. The pharmaceutical composition according to claim 11, characterized in that the other antiviral agent is selected from ribavirin, interferon, niclosamide, and combinations thereof.
13. Use of therapeutically effective doses of pyronaridine or pharmaceutically acceptable salts thereof in the manufacture of agents for the prevention or treatment of respiratory illness caused by coronavirus infection, namely COVID-19.
14. The use of therapeutically effective amounts of artemisinin or its derivatives in the manufacture of agents for the prevention or treatment of respiratory illness caused by coronavirus infection, namely COVID-19, The artemisinin derivative is selected from the group consisting of dihydroartemisinin, artesunate, artemether, and arteether.
15. The use of therapeutically effective amounts of pyronaridine or a pharmaceutically acceptable salt thereof, and therapeutically effective amounts of artemisinin or a derivative thereof, in the manufacture of agents for the prevention or treatment of respiratory illness caused by coronavirus infection, namely COVID-19, The artemisinin derivative is selected from the group consisting of dihydroartemisinin, artesunate, artemether, and arteether.
16. The use according to claim 13 or 15, characterized in that the pharmaceutically acceptable salt of pyronarizine is selected from the group consisting of phosphate, sulfate, hydrochloride, acetate, methanesulfonate, benzenesulfonate, toluenesulfonate, maleate, and fumarate.
17. The use according to claim 16, characterized in that the pharmaceutically acceptable salt of pyronarizine is a phosphate.
18. The use according to claim 15, characterized in that the weight ratio of pyronaridine or a pharmaceutically acceptable salt thereof to artemisinin or a derivative thereof is 10:1 to 1:
10.
19. The use according to claim 18, characterized in that the weight ratio of pyronaridine or a pharmaceutically acceptable salt thereof to artemisinin or a derivative thereof is 1:1 to 6:
1.
20. The use according to claim 19, characterized in that the weight ratio of pyronaridine or a pharmaceutically acceptable salt thereof to artemisinin or a derivative thereof is 3:
1.
21. The use according to claim 14 or 15, characterized in that the derivative of artemisinin is artesunate.
22. The use according to any one of claims 13 to 15, characterized in that the drug further comprises at least one other antiviral agent.
23. The use according to claim 22, characterized in that the other antiviral agent is selected from the group consisting of viral replication inhibitors, helicase inhibitors, viral protease inhibitors, and viral cell entry inhibitors.
24. The use according to claim 23, characterized in that the other antiviral agent is selected from ribavirin, interferon, niclosamide, and combinations thereof.